Prelude to the Best Sommelier of Canada Contest | SaltWireFRANKFURT - Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.
The Swiss drugmaker said in a statement that it expects group core operating income to grow by a percentage of"mid to high teens" in 2023, up from"low double-digit to mid teens" predicted previously.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SaltWire Network - 🏆 45. / 63 Read more »